Biodel Inc. officials, during a conference call with investors, sounded rightly happy about the top-line Phase II win with BIOD-123, an ultra-rapid-acting mealtime insulin for Type I diabetes, which proved non-inferior to Eli Lilly and Co.’s Humalog – but injection-site pain data between the two compound failed to match, and Wall Street moved the shares’ needle down instead of up.